Bioxytran CEO to Present at Noble Capital Markets' Emerging Growth Conference

David Platt, Ph.D. to provide overview of company's strategy and pipeline progress.

Published on Feb. 5, 2026

Got story updates? Submit your updates here. ›

Bioxytran, Inc., a clinical-stage biotechnology company focused on novel carbohydrate-based therapeutics, announced that CEO David Platt, Ph.D. will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 5, 2026. The presentation will feature a fireside-style Q&A session and provide an overview of Bioxytran's corporate strategy, pipeline, and clinical and regulatory progress.

Why it matters

Bioxytran is developing a portfolio of investigational therapies targeting complex disease mechanisms, including an antiviral candidate and programs focused on oxygen transport and galectin biology. The company's participation in this prominent investor conference signals its continued progress and efforts to raise awareness among the investment community.

The details

During the presentation, Dr. Platt will discuss Bioxytran's pipeline, which includes ProLectin-M, an investigational broad-spectrum antiviral candidate, as well as oxygen-transport and galectin-focused programs. The presentation will also cover the company's corporate strategy and previously disclosed clinical and regulatory milestones.

  • The presentation is scheduled for Thursday, February 5, 2026.

The players

Bioxytran, Inc.

A clinical-stage biotechnology company focused on the development of novel carbohydrate-based therapeutics.

David Platt, Ph.D.

Chief Executive Officer of Bioxytran, Inc.

Noble Capital Markets

An SEC / FINRA registered full-service investment bank and advisory firm hosting the Emerging Growth Virtual Equity Conference.

Got photos? Submit your photos here. ›

What’s next

The webcast of Dr. Platt's presentation will be archived on Bioxytran's website and Channelchek.com for 90 days following the event.

The takeaway

Bioxytran's participation in this prominent investor conference underscores the company's progress in advancing its pipeline of novel carbohydrate-based therapeutics and its efforts to engage with the investment community.